Quality control is the basic requirement for the conduct of clinical trials.

CECOG has proved to be a quality-oriented body with clearly defined decision lines acknowledged and certified by both, government inspections and industry-driven audits. All CECOG sites are subject to comonitorings. Thus, a smooth and correct conduct of each trial is guaranteed.

During the past years, CECOG successfully underwent the following inspections and audits:
  • Quality Assessment – Eli Lilly, September 2004
  • Quality Assessment – Eli Lilly, January 2005
  • Audit – Novartis, November 2004
  • Site Inspection – AGES (Austrian Health Authority), April 2006
  • Site Audit and CECOG office audit – Eli Lilly, April 2007
  • Quality Assessment – Merck, November 2008
  • Site Inspection Romania – FDA, March 2009
  • Site Inspection Serbia –MoH, September 2009
  • Site Inspection Israel –MoH, September 2009
  • Site Audit and CECOG office Audit – GEICAM, November 2016
  • Site Inspection Hungary – MoH, October 2017
  • Site Audit – GEICAM, June 2018
  • Site Audit – GEICAM, November 2018